6 completed, 1 terminated. 7 Phase 2, 1 Phase 3.
By phase and status
Follow rozanolixizumab: new trials by email Literature Review of rozanolixizumab trials Research Report on rozanolixizumab
Trials (filtered) newest first · largest first
All 7 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis rozanolixizumab - Generalized Myasthenia Gravis | Phase 2 / Phase 3 | Completed | 14 | 2024-06-14 | 2026-10-27 |
A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome rozanolixizumab, Placebo - Fibromyalgia | Phase 2 | Completed | 63 | 2022-12-21 | 2025-07-01 |
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis Rozanolixizumab, Placebo - Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | Phase 2 | Terminated | 12 | 2021-09-27 | 2025-05-31 |
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rozanolixizumab - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Completed | 21 | 2019-08-21 | 2022-11-03 |
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rozanolixizumab, Placebo - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Completed | 34 | 2019-03-26 | 2023-08-01 |
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis UCB7665, Placebo - Myasthenia Gravis | Phase 2 | Completed | 43 | 2017-05-15 | 2021-08-03 |
Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia UCB7665 - Thrombocytopenia | Phase 2 | Completed | 66 | 2016-03-02 | 2024-01-29 |
Conditions studied
Myasthenia Gravis (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Fibromyalgia (1) · Thrombocytopenia (1)
Sponsors
UCB Biopharma SRL (5) · UCB Biopharma S.P.R.L. (2)
Countries
Germany (5) · Spain (5) · United Kingdom (5) · Belgium (4) · United States (4) · Denmark (3) · France (3) · Italy (3) · Netherlands (3) · Australia (2) · Czechia (2) · Poland (2) · Bulgaria (1) · Canada (1) · Georgia (1)
Results publications
PMID 30130439, PMID 38729747, PMID 32886753, PMID 33219142, PMID 37166675, PMID 38099334, PMID 42748952
NIH funding
2016 (2), 2018 (1), 2019 (1)